Search

everythinglearnresearchcommunity

for

Search:↓

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.

Green tea extract helps prevent cell death and supports cell survival in hair cells exposed to a chemotherapy drug.

MK-5108 is safe and shows potential against tumors, especially alone.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.

The combination of encorafenib and binimetinib caused few skin issues.

Biological therapy boosts the immune system to effectively fight melanoma.

The new nanoparticles could improve melanoma treatment by working better than current options.

A woman with severe angioedema improved significantly after treatment with rituximab.

Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.

Cepharanthine shows promise as a potential lung cancer treatment by effectively killing cancer cells.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

Gefitinib can cause slower, finer, brittle, and curly scalp hair.

Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.

MPA increases cancer spread by boosting Eph A2 activity.

Sonidegib effectively treated advanced basal cell carcinoma with mild side effects.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

A 25-year-old man with multiple skin tumors was successfully treated with acitretin and methotrexate.